Key Drivers
- Very high gross-margin
- Significant cash burn
- Net-debt heavy
AIAI Summary
ADPT's shift from a binary R&D bet to a commercialization-first MRD (clonoSEQ) business means valuation now hinges on execution—sustained test-volume/reimbursement gains and lab-cost leverage can convert segment profitability into company-wide profits, but material net-debt, partnership revenue loss risk, and the need for flawless EMR/reimbursement execution make this a hold/watch until consistent margin conversion and debt reduction are demonstrated.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Very high gross-margin
- •Significant cash burn
- •Net-debt heavy
ADPT has strong unit economics and ample near-term liquidity but is loss-making with heavy operating cash burn, high debt and an elevated valuation that undermines its investment case.
Price Behavior
Key Price Behavior Insights:
- •Defined support
- •Resistance band
- •High volatility
Over the last month ADPT has traded in a short-term downtrend—about a 10–12% drop to $13.58 from $15.20—volatile between $12.45 support and $16.4–$16.5 resistance, implying possible oversold mean-reversion but elevated downside risk.
Large intra-month swings between $12.45 and ~$16.46 indicate heightened short-term volatility
Sentiment & News
Key News Insights:
- •Insider liquidity
- •Institutional trimming
- •Short-term uptick
Adaptive Biotechnologies saw large insider and institutional sell-offs (CEOs and COO sold millions of dollars of stock) even as the shares popped 5.8% intraday, signaling a liquidity-driven, likely short-lived rally rather than new operational strength. #insider-sales #transient-rally
Expect heightened volatility and a transient price reaction, with limited evidence this alters the company's underlying fundamentals
Similar Companies in Healthcare
Other companies in the same sector with AI ratings